Skip to Content

'
Scott E. Woodman, MD, PHD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
7455 Fannin Street
Unit Number: 904
Houston, TX 77054
Room Number: 1SCR2.3022
Phone: 713-792-2921
Fax: 713-563-3424

Education & Training

Degree-Granting Education

2004 Albert Einstein College of Medicine, New York, NY, MD, Medicine
2004 Albert Einstein College of Medicine, New York, NY, PHD, Molecular Pharmacology
2000 Albert Einstein College of Medicine, New York, NY, MS, Biomedical Science
1996 Michigan State University, East Lansing, MI, MA, Philosophy
1993 Hillsdale College, Hillsdale, MI, BS, Philosophy and Biology

Postgraduate Training

2007 Medical Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX
2004 Clinical Fellowship, Internal Medicine, Harvard Medical School, Boston, MA
2004 Clinical Residency, Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA

Board Certifications

2007 American Board of Internal Medicine

Honors and Awards

2012 Cancer Center Support Grant Faculty Awars, National Cancer Insitute, MD Anderson Cancer Center
2011 Rising STARS Award, University of Texas Systems
2010 Lupe C. Garcia Fellowship in Cancer Research, M. D. Anderson Cancer Center
2010 Melanoma SPORE Career Development Award, National Cancer Institute, MD Anderson Cancer Center
2010 National Eye Institute Travel Grant, Association for Research in Vision and Opthamology
2009 Merit Award, American Society for Clinical Oncology
2009 Paul Calabresi Award for Clinical Oncology, MD Anderson Cancer Center, National Institutes of Health
2009 Young Investigator Award, American Society of Clinical Oncology (ASCO)
2008 Carol Cogdell Courtney Fellowship, Melanoma Oncology, MD Anderson Cancer Center
2007 Ruth L. Kirschstein National Research Service Award, MD Anderson Cancer Center, National Institute of Health
2006-2007 Resident Teaching Award, Harvard Medical School Class of 2007
2005-2006 Outstanding Resident Teacher Award, Harvard Medical School, Shapiro Institute
2004 Alpha Omega Alpha Honor Society, Albert Einstein College of Medicine
1996-2004 Medical Scientist Training Program Grant, National Institutes Health

Professional Memberships

Alpha Omega Alpha, Honor Medical Society
Member, 6/2004
American Society of Clinical Oncology
Member, 6/2009
Association for Research in Vision and Ophthalmology
Member, 6/2010

Selected Publications

Peer-Reviewed Original Research Articles

1. Chattopadhyay C, Grimm EA, Woodman SE. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS One 9(2):e83957, 2014. e-Pub 2/2014. PMCID: PMC3923717.
2. Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol 39(9):821-5, 9/2012. e-Pub 7/19/2012. PMID: 22809251.
3. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE. Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner. Clin Cancer Res. e-Pub 7/19/2012. PMID: 22733540.
4. Griewank KG, Yu X, Khalili J, Sozen MM, Stempke-Hale K, Bernatchez C, Wardell S, Bastian BC, Woodman SE. Genetic and Molecular Characterization of Uveal Melanoma Cell Lines. PIGM CELL MELANOMA R 25(2):182-7, 3/2012. e-Pub 2/2012. PMCID: PMC3288394.
5. Woodman SE. Metastatic uveal melanoma: biology and emerging treatments. Cancer J 18(2):148-52, Mar-Apr, 3/2012. PMID: 22453016.
6. Woodman SE. BAP1tism of a Tumor Suppressor. Clin Cancer Res 18(2):323-5, 1/15/2012. e-Pub 12/2/2011. PMID: 22140212.
7. Woodman SE, Lazar AJ, Aldape KD, Davies MA. New Strategies in Melanoma: Molecular Testing in Advanced Disease. Clin Cancer Res. e-Pub 1/24/2012. PMID: 22275506.
8. Deng W, Vashisht Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. PIGM CELL MELANOMA R. e-Pub 12/2011. PMID: 22171948.
9. Patel SP, Woodman SE. Profile of ipilimumab and its role in the treatment of metastatic melanoma. DRUG DES DEV THER 5:489-95, 2011. e-Pub 12/2011. PMID: 22267918.
10. Woodman SE, Mills GB. Are oncogenes sufficient to cause human cancer? P NATL ACAD SCI USA 107(48):20599-600, 11/2010. e-Pub 11/2010. PMCID: PMC2996413.
11. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70(21):8736-47, 11/2010. e-Pub 10/2010. PMID: 20959481.
12. Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80(5):568-74, 9/2010. e-Pub 5/2010. PMID: 20457136.
13. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 15(24):7538-7546, 12/2009. PMCID: PMC2805170.
14. Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, Kim KB, Woodman S, Davies M, Plaza JA, Nash JW, Prieto VG, Lazar AJ, Ivan D. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 22(11):1446-56, 11/2009. e-Pub 8/2009. PMID: 19718013.
15. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8(8):2079-85, 8/2009. e-Pub 8/2009. PMID: 19671763.
16. Quintás-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P, Medscape. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 5(12):737-40, 12/2008. e-Pub 10/21/2008. PMID: 18936790.
17. De Souza AP, Cohen AW, Park DS, Woodman SE, Tang B, Gutstein DE, Factor SM, Tanowitz HB, Lisanti MP, Jelicks LA. MR imaging of caveolin gene-specific alterations in right ventricular wall thickness. Magn Reson Imaging 23(1):61-8, 1/2005. PMID: 15733789.
18. Woodman SE, Cheung MW, Tarr M, North AC, Schubert W, Lagaud G, Marks CB, Russell RG, Hassan GS, Factor SM, Christ GJ, Lisanti MP. Urogenital alterations in aged male caveolin-1 knockout mice. J Urol 171(2 Pt 1):950-7, 2/2004. PMID: 14713860.

Abstracts

1. Woodman SE, Yu X, Chattopadhyay C, Williams M, Poindexter N, Jager MJ, Grimm E, Esmaeli B. GNAQ/11 Mutant Dependent Uveal Melanoma Sensitivity to MEK and PI3K Inhibitors. International Society of Ocular Oncology International Meeting, 2011. e-Pub 11/2011.
2. Woodman SE, Yu X, Chattopadhyay C, Poindexter N, Grimm E. GNAQ/11 Mutant Dependent Uveal Melanoma Sensitivity to MEK and PI3K Inhibitors. National Cancer Institute Translational Science Meeting, 2011. e-Pub 7/2011.
3. Woodman SE, Yu X, Chattopadhyay C, Williams M, Poindexter N, Jager MJ, Grimm E, Esmaeli B. GNAQ/11 Mutant Dependent Uveal Melanoma Sensitivity to MEK and PI3K Inhibitors. Association for Research in Vision and Ophthalmology Annual Meeting, 2011. e-Pub 5/2011.

Last updated: 7/9/2014